Let's consider one company in each category. The one that could benefit from Anthropic's IPO is Broadcom ( AVGO -5.48%), and ...

Lilly is the maker of tirzepatide, a drug sold under the name Mounjaro for type 2 diabetes and as Zepbound for weight loss.

The e-commerce company has beaten its own forecast all year. Is a cheaper stock enough to buy ahead of the next one?

Considering the pros and cons, it's fair to assume Palantir will track with the S&P 500 average annual return of around 10%. Based on a $197 price on Oct. 29, that would put it around $216 by the end ...

Normalized EBITDA margins expanded to more than 33%, giving management room to fund growth and return capital through ...

The Schwab U.S. Dividend Equity ETF has a current yield of 3.1%. To generate the equivalent of $1,000 per month in dividend ...

Apple ( AAPL -1.23%) has been sneakily delivering a strong 2026. It's up about 27% this year, easily outperforming the market ...

Amgen has been posting strong financial results. In the second quarter, the company's revenue increased by 10% year over year ...

The only real exceptions to the "claims up, stocks down" rule is the late 1980s, when initial jobless claims started moving ...

Structural cost cuts and market share gains in a downturn hint at what AGCO could deliver when farm economics recover.

Adobe operates on a subscription platform, which makes its revenue fairly steady. Despite everyone being worried about AI ...

Record contracted backlog of $1.8 billion at the company's share secures multiyear revenue visibility through 2028.